


12TH ANNUAL CHAIR SUMMIT

Master Class for Neuroscience Professional Development

February 27-29, 2020 | The LINQ | Las Vegas, Nevada

Provided by






Progress in Suicide Prevention

Charles B. Nemeroff, MD, PhD

Professor and Chair, Department of Psychiatry
Mulva Clinic for the Neurosciences
Director, Institute of Early Life Adversity Research
Dell Medical School
The University of Texas at Austin
Austin, TX




Charles B. Nemeroff, MD, PhD Disclosures


- Research/Grants: National Institutes of Health (NIH)
- Consultant: ACADIA Pharmaceuticals Inc.; Bracket (Clintara); EMA Wellness; Gerson Lehrman Group, Inc. (GLG); Intra-Cellular Therapies, Inc.; Janssen Research & Development LLC; Magstim, Inc.; Navitor Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; TC MSO, Inc.; Xhale, Inc.
- **Stockholder:** AbbVie Inc.; Antares Pharma; BI Gen Holdings, Inc.; Celgene Corporation; Corcept Therapeutics; EMA Wellness; OPKO Health Inc.; Seattle Genetics, Inc.; TC MSO, Inc.; Trends in Pharma Development, LLC; Xhale, Inc.
- Advisory Board: American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); Bracket (Clintara); Brain & Behavior Research Foundation (BBRF); Laureate Institute for Brain Research, Inc.; Skyland Trail; Xhale, Inc.
- Board of Directors: American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); GratitudeAmerica, Inc.; Xhale, Inc.
- Income Sources or Equity of \$10,000 or More: American Psychiatric Publishing; Bracket (Clintara);
 CME Outfitters, LLC; EMA Wellness; Intra-Cellular Therapies, Inc.; Magstim, Inc.; Xhale, Inc.
- Patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1); Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2); Compounds, Compositions, Methods of Synthesis, and Methods of Treatment (CRF Receptor Binding Ligand) (US 8,511,996B2)

Learning Objective

Evaluate latest evidence regarding risk and protective factors for suicide




U.S. Suicide Facts: 1970-2015



U.S. Suicide Facts: 2017 CDC


- 47,173 suicides
- 129/day, every 12 min in U.S.
- 10th leading cause of death in U.S.
 - 2nd for 15-34 yr, 4th for adults 24-64 yr
- Regional & demographic differences
- Veterans rate 20% higher than age-matched
- For every death ~25 suicide attempts
 - 1.4M adults attempt annually
- 60% of Americans experience loss to suicide
- Suicide rate greatly exceeds the homicide rate
- > 500,000 visits to emergency rooms due to self-harm

U.S. Suicide Rates by Age











U.S. Suicide Rates by Sex: 1981-2014




Methods of Suicide Death in U.S.



Suicide Rates and the Declining Psychiatr Hospital Bed Capacity in the U.S.






per 100 000 Residents

Gibbons RD, et al. JAMA Psychiatry. 2017;74:849-850.


Crude Rates of Suicide by Calendar Year Among Veterans (V) and Civilians (C) Ages 18-29




Main Finding: Rates of suicide have increased substantially among younger Veterans while remaining relatively stable among civilians ages 18–29.

U.S. Department of Veterans Affairs

Interacting Risk and Protective Factors



Suicide Deaths and Major Psychiatric Syndromes



A number of psychological autopsy studies have found that approximately 90% of all completed suicides could be retrospectively diagnosed with a major mental disorder

Risk Factors for Suicide

- Mental health conditions
- Previous suicide attempt
- Serious physical illness/chronic pain
- Specific symptoms
- Family history of mental illness and suicide
- Childhood trauma



Protective Factors

- Strong support
- Connectedness
- Strong therapeutic alliance
- Accessing mental health care



JAMA Psychiatry | Original Investigation


Risk of Suicide After Cancer Diagnosis in England

Katherine E. Henson, MSc, DPhil; Rachael Brock, MB, BChir; James Charnock, MSCi; Bethany Wickramasinghe, BSc; Olivia Will, MBChB, PhD, FRCS; Alexandra Pitman, MSc(Econ), MBBS, MRCPsych, PhD

JAMA Psychiatry. 2019;76(1):51-60. doi:10.1001/jamapsychiatry.2018.3181Published online November 21, 2018.


Henson K, et al. JAMA Psychiatry. 2019. 76;51-60.

Figure. Suicide Standardized Mortality Ratios (SMRs) and Absolute Excess Risks (AERs) per 10 000 Person-Years at Risk by Follow-up Period



Estimates of SMRs (A) and AERs (B) are presented in eTable 5 in the Supplement. Error bars indicate 95% Cls.

Henson K, et al. JAMA Psychiatry. 2019. 76;51-60.



JAMA Psychiatry | Original Investigation

Positron Emission Tomographic Imaging of the Serotonergic System and Prediction of Risk and Lethality of Future Suicidal Behavior

Maria A. Oquendo, MD; Hanga Galfalvy, PhD; Gregory M. Sullivan, MD; Jeffrey M. Miller, MD; Matthew M. Milak, MD; M. Elizabeth Sublette, MD, PhD; Sebastian Cisneros-Trujillo, MD; Ainsley K. Burke, PhD; Ramin V. Parsey, MD, PhD; J. John Mann, MD

JAMA Psychiatry. 2016;73(10):1048-1055. doi:10.1001/jamapsychiatry.2016.1478Published online July 27, 2016. Corrected on August 24, 2016.

Oguendo M, et al. JAMA Psychiatry. 2016.73;1048-1055.

Childhood Abuse, Household Dysfunction, and the Risk of Attempted Suicide Throughout the Life Span: Findings From the Adverse Childhood Experiences Study

Shanta R. Dube, MPH; Robert F. Anda, MD, MS;


Vincent J. Felitti, MD; Daniel P. Chapman, PhD;

David F. Williamson, PhD; Wayne H. Giles, MD, MS

Dube SR et al. JAMA. 2001;286:3089-3096.

Prevalence of multiple childhood adverse experiences (ACEs) and association between number of ACEs and lifetime history of attempted suicide (n = 17,337)

Adapted from: Dube SR et al. JAMA. 2001;286:3089-3096.



The role of inflammatory cytokines in suicidal behavior: A systematic review

Gianluca Serafini^{a,*}, Maurizio Pompili^a, Maria Elena Seretti^a, Henry Stefani^a, Mario Palermo^a, William Coryell^b, Paolo Girardi^a

^aDepartment of Neurosciences, Mental Health and Sensory Organs—Suicide Prevention Center, Sapienza University of Rome, Sant'Andrea Hospital, 1035-1039 Via di Grottarossa, Rome 00189, Italy ^bDepartment of Psychiatry, University of Iowa, Carver College of Medicine, 500 N Road, Iowa City, IA 52231-1190, United States

European Neuropsychopharmacology (2013) 23, 1672-1686

Serafini G, et al. Euro Neuropsychopharm. 2013;23:1672-1686.

Timing Matters

- Intense suicidal urge is short
- Transitions in life are higher risk times
- Ambivalence is at play: mixture of desire to live versus to die/escape pain



Means Matter

- Limiting access to lethal means saves lives and drives down rates for entire regions
 - -Coal gas (UK)
 - Bridge barriers
 - -Pesticides (Asia)
 - Medication blister pkg
 - -Firearms policy changes (Israel)



SMART Goals

Specific, Measurable, Attainable, Relevant, Timely

- Individual and social/cultural factors can create risk for or protection against suicide.
- Evaluate your patients for
 - Biological factors
 - Psychological factors
 - Social/environmental factors
- Talk with patients about protective factors when developing treatment plans
 - Connectedness
 - Therapeutic alliance
 - Access to mental health care/team

Questions Answers

Don't forget to fill out your evaluations to collect your credit.

